AstraZeneca, Sun Pharma Partner to Distribute Hyperkalaemia Treatment Across India
An exclusive brand alliance was established on 18 November by AstraZeneca Pharma India and Sun Pharmaceutical Industries to increase the availability of sodium zirconium cyclosilicate (SZC), a therapy for hyperkalaemia, in the Indian market. Both businesses will market and distribute SZC under different brand names as part of the agreement.